Поскольку можно предполагать наличие функциональной автономии, то в отношении тиреостатиков, на мой взгляд, нужно руководствоваться следующими рекомендациями из гайда [
Ссылки доступны только зарегистрированным пользователям ]:
Цитата:
■ RECOMMENDATION 65
When TSH is persistently <0.1 mU/L, treatment of SH should be strongly considered in all individuals ≥65 years of age, and in postmenopausal women who are not on estrogens or bisphosphonates; patients with cardiac risk factors, heart disease or osteoporosis; and individuals with hyperthyroid symptoms. 2/++0
■ RECOMMENDATION 49
We suggest that long-term methimazole treatment of TMNG or TA be avoided, except in some elderly or otherwise ill patients with limited longevity who are able to be monitored regularly, and in patients who prefer this option. 2/+00
Technical remarks: Because long-term, low-dose ATD treatment in nodular hyperthyroidism can be difficult to regulate, frequent (every 3 months) monitoring is recom¬mended, especially in the elderly.
|